BioSpace News Archive

WARSAW, Ind., Feb. 26, 2020 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (NASDAQ: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, is pleased to announce that it was recently named one of the Best Places to Work in Indiana by the Indiana Chamber of Commerce and Best Companies Group. OrthoPediatrics’ recognition and inclusion in the fifteenth annual program is the fourth time the Company has been honored with this award. OrthoPediatrics’ President and Chief

Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it has completed the acquisition of InstruNor AS, the privately held provider of the only fully integrated sample preparation system for flow and mass cytometry.

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced final follow-up data for its Phase 1/2 study of GPS in patients with acute myeloid leukemia (AML) in second complete remission (CR2).

Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) (“Cryoport”), the world’s leading temperature-controlled logistics company dedicated to the life sciences industry, today announced a multi-year agreement with Inception Fertility, LLC

- Distinguished Career at the U.S. Food and Drug Administration in CDER and the Office of Women’s Health; Significant Industry and Regulatory Expertise -

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), with Toronto Memory Program, Canada’s largest and most experienced memory clinic and site for drug treatment trials in Alzheimer’s disease (AD) has initiated a pilot longitudinal study to assess the level of blood-based biomarkers in early AD with the support of Parexel, one of the world’s leading global clinical research organizations (CROs).

-- Reported favorable interim data from Phase 1/2 study of M254 in ITP, supporting expansion of Part B; expect to report updated data in Q2 2020 and launch additional Phase 2 study in CIDP in Q4 2020 -- -- Target enrollment completed in nipocalimab Phase 2 Vivacity-MG study; top-line proof-of-concept results expected in Q3 2020 -- -- Expanded pipeline with nomination of M267, a new SIFbody development candidate targeting CD38; plan to initiate IND-enabling studies in 2020 -- -- Ended 2

Zomedica Pharmaceuticals Corp., a veterinary diagnostic company, announced consolidated financial results for the year ended December 31, 2019.

Ascletis Pharma Inc. announces the advancement in Novel Coronavirus Pneumonia clinical trial of oral Ganovo® and Ritonavir combination therapy, led by Dr. Hongyi CHEN, the director of the Ninth Hospital of Nanchang.

AHF asks FTC and DOJ to strengthen Draft 2020 Vertical Merger Guidelines.